title: Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections.
abstract: Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling medical devices requires lengthy antibiotic therapy and adequate surgical debridement. Teicoplanin, a glycopeptide antibiotic with a long half-life, was used three-times weekly in the treatment of these infections. After a period of daily dosing with teicoplanin, patients were treated with an intravenous dose of 12 mg on mondays, wednesdays and fridays. A control group of patients were treated with teicoplanin daily. Teicoplanin levels were measured during the study. Thirty-six patients were enrolled in the study: 14 with vertebral osteomyelitis, 12 with infected orthopedic implants, 7 with osteomyelitis and 3 with arterial prosthetic infections. The duration of treatment ranged from 60 to 360 days. Cure was obtained in 21 (58%) patients and improvement in 15 (42%) patients. Trough and peak serum concentrations in three-time weekly patients were 16.2+/-7.2 mg/l and 58.7+/-14.4 mg/l. In the control group trough and peak serum concentrations were 18.9+/-13.6 mg/l and 52.2+/-27 mg/l. Adverse events occurred in 6 patients: mainly mild liver toxicity. Three times weekly teicoplanin seems to be a valuable option in the treatment of chronic infections.
authors.affiliation: Infectious Diseases Unit, Cisanello Hospital, Pisa, Italy. c.tascini@ao-pisa.toscana.it
authors.forename: C
authors.initials: C
authors.lastname: Tascini
authors.forename: E
authors.initials: E
authors.lastname: Tagliaferri
authors.forename: A
authors.initials: A
authors.lastname: Di Paolo
authors.forename: L
authors.initials: L
authors.lastname: Ciofi
authors.forename: M
authors.initials: M
authors.lastname: Del Tacca
authors.forename: P
authors.initials: P
authors.lastname: Lambelet
authors.forename: F
authors.initials: F
authors.lastname: Menichetti
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood; D002908:Chronic Disease; D006801:Humans; D016106:Methicillin Resistance; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology; D010045:Outpatients; D016459:Prosthesis-Related Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000302:isolation & purification; D017334:Teicoplanin / Q000008:administration & dosage* / Q000097:blood
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin